Essential tips for optimising treatment in your patients with HFrEF Professor Andrew Sindone
The Hidden Symptoms of Heart Failure: How to find them and how to act Professor Andrew Sindone
Heart Failure. A GP disease state: A guide to optimising your patient’s treatment Professor Andrew Sindone
When should a GP intervene in a patient's heart failure management? Dr Gary Deed and Dr Anita Sharma
Why should there be an urgency to treat a heart failure patient? A/Prof. John Atherton
Who is the right patient for a GP to initiate Entresto on? Dr Gary Deed and Dr Anita Sharma
Mechanisms of myocardial injury from COVID-19 and the clinical implications Dr Yee Weng Wong
Should we avoid ACEI ARB medications in COVID-19 patients? Dr Yee Weng Wong
Chronic Heart Failure and COVID-19: What you need to know in 90 seconds Dr Yee Weng Wong
Why HF Hospitalisation Matters Dr Scott McKenzie
Re-framing HF Hospitilisation Dr Scott McKenzie
COVID-19 and HF Questions Answered Dr Scott McKenzie
What is your experience with treating an in-hospital patient with Entresto? Professor Fabian Knebel
When should a clinician consider switching a stable patient to Entresto? Professor Fabian Knebel
Are there any stable heart failure patients? Professor Fabian Knebel
1. ENTRESTO Approved Product Information, 08 November 2017.
Entresto is indicated in adult patients for the treatment of chronic heart failure (NYHA Class II-IV) with reduced ejection fraction.
PBS Information : Authority required (STREAMLINED) for chronic heartfailure. Patients must be NYHA Class II–IV, have LVEF ≤40% and be receiving optimal standard chronic heart failure treatment.
Refer to PBS Schedule for full Authority Information.
SEE APPROVED PRODUCT INFORMATION BEFORE PRESCRIBING. FOR THE MOST UP TO DATE PRODUCT INFORMATION CLICK HERE.